** WARNING, Not error free yet, under construction: check result to a standard work. **

Trazodone

From MedicaWiki
Revision as of 17:15, 20 May 2011 by Walter (Talk | contribs)


Jump to: navigation, search
trazodone
Type antidepressant
Group other
links
ATC-code N06AX05
CAS-number 19794-93-5
Medscape 342965
PubChem 5533
PubMed trazodone
Drugs.com trazodone-hydrochloride
drugbank APRD00533
Kompas (nl) trazodone
Wikipedia trazodone
more info
DDD 300mg [1]
Cth 800-1600μg/L [2]
Ctox 2000μg/L [2]
T1/2 7h [1]
metabolites 5[1]
bioavailability 65%[1]
administration oral
tablets 100 mg [3]
Price/day 1 [4]

trazodone is an antidepressant in the group other.


Caution area Value Ref Description
Lactation 8 [5][6] Unsafe and possibly harming
Pregnancy 3 [6][7] possibly safe - B2* - available data show no evidence of an increased occurrence of fetal damage
Diabetes mellitus 2 [3][8] very weak influence on diabetes - probably safe, consider monitoring
Hepatic insufficiency 8 [6] Unsafe with mild hepatic impairment (Child-Pugh classification A - monitoring required)
Children 10 [6][9] absolutely inapplicable - not registered, nor studied
Elderly 6 [5][10][11] average safety - adapt dosage
Dementia 8 [6] strong influence on cognition
Chronic Obstructive Pulmonary Disease 2 [12] safe - no adaptation needed, if well-monitored
Hypertension 8 [13] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Hypotension 8 [13] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Heart failure 8 [1][13] strong influence on HF - rather unsafe, continue only if absolutely necessary
Long QT-syndrome 6 [14][15][10] Conditional risk of QT prolongation and/or TdP* - frequent ECG-monitoring recommended Arizona Scale - Conditional TdP Risk
Seizures 3 [3] rare (between 1 in 1,000 and 1 in 10,000 patients: 0,01% - 0,1%)
Cerebrovascular accidents 8 [1][13] strong influence on CVA - only applicable with frequent monitoring
Renal insufficiency 4 [16] unsafe when MDRD between 10 - 30 (severe renal impairment, monitoring required)
Dyskinesia 6 [13] uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%)
Movement disorders 8 [13] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Haematology 6 uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%)
Anticholinergic effects 10 [6][10][13] very common (over 1 in 10 patients: > 10%)
Male sexual dysfunction 6 [6][10] uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%)
Female sexual dysfunction 2 [18][19] very rare (less then 1 in 10,000 patients: < 0,01% )
Traffic 10 [20] severe influence (category III) >0,8 g/l (>0,8‰)
Weight 8 [6][21][13] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Weight gain 0 unknown/unverified
Weight loss 0 unknown/unverified
Photosensitivity 0 unknown/unverified
Sedation 10 [6][10][13] very common (over 1 in 10 patients: > 10%)
Poor CYP2D6 metabolizer 0 unknown/unverified
Ultra rapid CYP2D6 metabolizer 0 unknown/unverified
Poor CYPC19 metabolizer 0 unknown/unverified
Ultra rapid CYP2C19 metabolizer 0 unknown/unverified


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 KNMP; Informatorium Medicamentorum 2009; Monografie "trazodon" (Dutch)
  2. VU Medisch Centrum, Referentiewaarden klinisch farmacologisch bepalingen
  3. 3.0 3.1 3.2 CVZ; Farmacotherapeutisch Kompas - trazodon (dutch)
  4. oraal 16.64/maand/DDD cf FTK: results in €0.55
  5. 5.0 5.1 Winthrop Pharmaceuticals UK Ltd; SPC Molipaxin 50mg Capsules
  6. 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 GenRx B.V.; SPC Trazodone (Dutch)
  7. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G; A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy; Can J Psychiatry. 2003 Mar;48(2):106-10  (pubmed-id 12655908)
  8. Bazire S. Psychotropic drug directory 2007. Trowbridge: Cromwell Press; 2007
  9. Medline; Trazodone
  10. 10.0 10.1 10.2 10.3 10.4 Mendelson WB; A review of the evidence for the efficacy and safety of trazodone in insomnia; J Clin Psychiatry. 2005; Apr;66(4): 469-76  (pubmed-id 15816789)
  11. Haria M, Fitton A, McTavish D; Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders; Drugs Aging. 1994 Apr;4(4):331-55  (pubmed-id 8019056)
  12. Roth T; Hypnotic use for insomnia management in chronic obstructive pulmonary disease; Sleep Med. 2009 Jan;10(1):19-25. Epub 2008 Aug 9  (pubmed-id 18693067)
  13. 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 Drugs.com trazodone-hydrochloride
  14. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce Torsade de Pointes. Drug Saf 2002;25(4): 263-86  (pubmed-id 11994029)
  15. Arizona Scale
  16. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines, 10th edition. London: Informa Healthcare; 2009
  17. Silverstone PH, Rue JE, Franklin M, Hallis K, Camplin G, Laver D, Cowen PJ; The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers; Int Clin Psychopharmacol. 1994 Sep;9(3):173-8  (pubmed-id 7814826)
  18. Purcell P, Ghurye R; Trazodone and spontaneous orgasms in an elderly postmenopausal woman: a case report.; J Clin Psychopharmacol. 1995 Aug;15(4):293-5  (pubmed-id 7593719)
  19. Gartrell N; Increased libido in women receiving trazodone; Am J Psychiatry. 1986 Jun;143(6):781-2  (pubmed-id 3717405)
  20. The International Council on Alcohol, Drugs and Traffic Safety (ICADTS). ICADTS drug list - July 2007 (Internet)
  21. Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA; Comparison of bupropion and trazodone for the treatment of major depression; Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA  (pubmed-id 8027413)